Drug Screening Identifies Sigma-1-Receptor as a Target for the Therapy of VWM Leukodystrophy

Drug Screening Identifies Sigma-1-Receptor as a Target for the Therapy of VWM Leukodystrophy

Vanishing white matter (VWM) disease is an autosomal genetic leukodystrophy caused by mutations in subunits of eukaryotic translation initiation factor 2B (eIF2B). The clinical symptoms exhibit progressive loss of white matter in both hemispheres of the brain, accompanied by motor functions deterior...

Full description

Bibliographic Details
Main Authors: Andrea Atzmon, Melisa Herrero, Reut Sharet-Eshed, Yocheved Gilad, Hanoch Senderowitz, Orna Elroy-Stein
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Molecular Neuroscience
Subjects:
leukodystrophy
drug screening
vanishing white matter (VWM)
mitochondria dysfunction
eIF2B
Sigma-1-Receptor (S1R)
Online Access:https://www.frontiersin.org/article/10.3389/fnmol.2018.00336/full

Internet

https://www.frontiersin.org/article/10.3389/fnmol.2018.00336/full

Similar Items